Syndax Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Syndax Pharmaceuticals, Inc. on June 9, 2020. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders:
- Proposal 1: Election of Directors All three nominees were elected to serve three-year terms until the 2023 Annual Meeting.
- Fabrice Egros, Ph.D.: 18,002,091 For; 3,076,552 Withheld.
- Pierre Legault: 17,524,059 For; 3,554,584 Withheld.
- Michael A. Metzger: 20,561,832 For; 516,811 Withheld.
- Proposal 2: Ratification of Auditors Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- For: 27,608,953
- Against: 148,681
- Abstain: 10,075
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Key Facts for Investor Verification
- Confirm the tenure of the newly elected directors (Fabrice Egros, Pierre Legault, and Michael A. Metzger) through the 2023 Annual Meeting.
- Verify the appointment of Deloitte & Touche LLP as the auditor for the fiscal year ending December 31, 2020.
- Note the significant number of broker non-votes (6,689,066) recorded for the director election proposals.